Absolute Contraindications Active malignancy Pregnancy and lactation Severe hypoglycemia disorders Known hypersensitivity to IGF-1 Active proliferative retinopathy Relative Contraindications Diabetes mellitus Renal impairment Cardiac impairment History of hyperplasia Family history of certain cancers Severe hepatic impairment Dosing & Administration Starting Dose 2050 mcg/day subcutaneously Begin at the lower end for sensitive patients Assess tolerance for 12 weeks before titration Therapeutic Range 50120 mcg/day for most indications Maximum dose: 200 mcg/day Individualize dosing based on response and tolerance Cycling Protocol 46 weeks on therapy 4 weeks off therapy Helps prevent receptor desensitization Supports long-term efficacy Administration Guidelines Hypoglycemia Prevention: Always administer IGF-1 LR3 with or shortly after carbohydrate-containing meals
Signs include hives, swelling of the lips, tongue, or face, and severe dizziness
We will conduct a thorough consultation, explain your options and ensure your skin care journey is on the correct path
However, the severity of ME/CFS means that family members or caretakers are also severely impacted
See how PlexusDx does it differently: explore the Weight Management Protocols for semaglutide and tirzepatide with genetic context, or begin upstream and take the Precision Peptide Genetic Test to map your GLP-1 pathway first
Exploring bacterial metabolites in microbe-human host dialogue and their therapeutic potential in Alzheimers diseases
